<DOC>
	<DOCNO>NCT01436500</DOCNO>
	<brief_summary>A study ifetroban treatment hepatorenal syndrome ( HRS ) hospitalize adult patient assess safety pharmacokinetics 3 day intravenous ifetroban .</brief_summary>
	<brief_title>Safety Pharmacokinetics Ifetroban Hepatorenal Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Ifetroban</mesh_term>
	<criteria>1 . Chronic liver disease , define cirrhosis ascites base clinical finding ( biopsy necessary ) . 2 . Subjects either Type 1 Type 2 HRS define b : . Type 1 : . At least double serum creatinine minimum 220 µmol/L ( 2.5 mg/dL ) enrollment , occur period le 14 day , OR ii . A 50 % great reduction estimate glomerular filtration rate ( GFR calculate method CockcroftGault ) 20 mL/min enrollment occur period le 14 day . iii . A projected doubling serum creatinine minimum 2.5 mg/dL , expect occur less 14 day base rate change observe . b . Type 2 : define least 33 % reduction creatinine clearance occur period great 2 week , serum creatinine ( SCr ) &gt; 133µmol/L ( 1.5 mg/dL ) . 3 . Oliguria occur within 48 hour prior first administration CTM . Oliguria define average urine output &lt; 35 mL/hr ( measure minimum 4 hour ) either follow circumstance : . When measured central venous pressure ( CVP ) &gt; 12 mmHg , OR b. follow fluid challenge consist either : i. minimum 20 mL/kg isotonic fluid ( e.g . combination 5 % albumin , normal saline , blood blood product ) give 6 hour ii . minimum 1 g/kg hypertonic fluid ( e.g . 25 % albumin ) give 24 hour iii . equivalent combination 3.b.i 3.b.ii 1 . History allergy hypersensitivity ifetroban 2 . Pregnant nursing 3 . Less 18 year age 4 . Serum creatinine time enrollment great equal 5.0 mg/dL 5 . Platelet count screen less 30 x 10^3 platelets/µL 6 . Anticipated plan need dialysis within 5 day first CTM dose . 7 . Active gastrointestinal hemorrhage ( active define evidence bleed within 48 hour first dose CTM ) 8 . Evidence current ( within past 30 day ) obstructive ( postrenal ) intrinsic renal disease [ include limited : acute tubular necrosis ( ATN ) , glomerular diseases/glomerulonephritis , acute interstitial nephritis ( AIN ) , know urinary obstruction , proteinuria &gt; 500 mg/day , microhematuria ( &gt; 50 RBCs/high power field ) , abnormal renal ultrasound , fractional excretion sodium ( FeNa ) &gt; 2.0 % , urinary cast hyaline . 9 . Current recent ( within precede 5 day ) treatment nephrotoxic drug include limited : NSAIDs ( prior 48 hour ) , angiotensin convert enzyme ( ACE ) inhibitor , angiotensin receptor blocker ( ARB ) , calcineurin inhibitor ( cyclosporine , tacrolimus ) , aminoglycosides , amphotericin B , antiretrovirals antiviral ( adefovir , cidofovir , tenofovir , acyclovir , indinavir ) , cisplatin , methotrexate , cyclosporine , amphotericin B contrast agent , foscarnet , zoledronate , etc . 10 . Presence shock define hypotension , mean arterial pressure le 50 mmHG . 11 . New York Heart Association class 3 4 heart failure . 12 . Presence hepatocellular carcinoma transplantable Milan criterion 13 . Cardiopulmonary arrest without full recovery mental status 14 . Moribund death expect within five day 15 . Bacterial fungal infection unresponsive least 24 hour appropriate antimicrobial therapy 16 . Burns &gt; 30 % body surface area 17 . Exposed investigational drug within 30 day 1st CTM administration . 18 . Inability understand requirement study . ( Subjects must willing provide write informed consent consent legally recognize representative , evidence signature inform consent document approve Institutional Review Board [ IRB ] , agree abide study restriction . If subject incapacitate , informed consent seek legally recognize representative ) . 19 . Refusal provide write authorization use disclosure protect health information . 20 . Be otherwise unsuitable study , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatorenal Syndrome</keyword>
	<keyword>HRS</keyword>
	<keyword>ifetroban</keyword>
</DOC>